Q-omics provides the consensus-scored OMG profile across patient tissues and cancer cell-line models. OMG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OMG is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, OMG protein abundance shows 28,686 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where OMG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OMG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OMG survival associations across molecular data types. OMG RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OMG RNA expression–survival associations across cancer types. High OMG expression shows unfavorable associations in KIRC, ACC and KICH, but favorable associations in BRCA, LGG and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OMG RNA expression.
This table summarizes OMG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for OMG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OMG shows lower tumor expression in LUAD, LUSC, THCA, COAD and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher OMG RNA expression in tumor versus normal tissue (log2 FC = +0.205, t-test p < 0.001).
This table shows molecular features associated with OMG in patient tissues and cancer cell lines. In patient samples, OMG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OMG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
